Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.72 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.47 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NQO2 | P16083 | 1/20 | 0.41 |
| ▸ | S100B | P04271 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451595 | 1.00 | POLB (0.72) | POLBL3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL3859217 | 0.91 | POLB (0.72) | POLBL3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL3852430 | 0.91 | POLB (0.72) | POLBL3MBTL1MAPTNPSR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3853378 | 0.89 | POLB (0.69) | POLBL3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL9520839 | 0.84 | L3MBTL1 (0.60) | POLBL3MBTL1MAPTALDH1A1CYP3A4 | |
| SCHEMBL5946312 | 0.84 | L3MBTL1 (1.00) | POLBL3MBTL1MAPTNPSR1ALDH1A1 | |
| SCHEMBL30723004 | 0.84 | L3MBTL1 (0.60) | POLBL3MBTL1MAPTALDH1A1CYP3A4 | |
| SCHEMBL525676 | 0.84 | L3MBTL1 (0.60) | POLBL3MBTL1MAPTALDH1A1CYP3A4 | |
| SCHEMBL5866562 | 0.83 | POLB (0.59) | POLBL3MBTL1MAPTNPSR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3333737 | 0.82 | L3MBTL1 (0.58) | POLBL3MBTL1MAPTALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 113 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12629367-B2 | Five-membered ring-fused six-membered ring compound, preparation method therefor, and pharmaceutical composition and use thereof | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2026-05-19 | — | — | US | disclosed |
| US-20250255864-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250255863-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2025-08-14 | — | — | US | disclosed |
| US-20250214972-A1 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2025-07-03 | — | — | US | disclosed |
| US-12343343-B2 | Five-membered ring-fused six-membered ring compound, preparation method therefor, and pharmaceutical composition and use thereof | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2025-07-01 | — | — | US | disclosed |
| EP-4516787-A9 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Hangzhou Polymed Biopharmaceuticals, Inc. (CN) | 2025-05-28 | — | — | EP | disclosed |
| US-12281098-B2 | Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2025-04-22 | — | — | US | disclosed |
| EP-4516787-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Hangzhou Polymed Biopharmaceuticals, Inc. (CN) | 2025-03-05 | — | — | EP | disclosed |
| CN-119409684-A | Five-membered and six-membered compound, preparation method, pharmaceutical composition and application | 杭州多域生物技术有限公司 | 2025-02-11 | — | — | CN | disclosed |
| US-20240423977-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | HANGZHOU POLYMED BIOPHARMACEUTICALS, INC. (CN) | 2024-12-26 | — | — | US | disclosed |
| US-20130345240-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2013-12-26 | — | — | US | disclosed |
| EP-2665724-A1 | BICYCLIC INHIBITORS OF ALK | AbbVie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-8546403-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2013-10-01 | — | — | US | disclosed |
| EP-2563776-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | Calcimedica, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| WO-2012097682-A1 | BICYCLIC INHIBITORS OF ALK | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011139489-A2 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA INC. (US) | 2011-11-10 | — | — | WO | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423977-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, IRAK1, IRAK2 | POLB 4214/4885L3MBTL1 3799/4885MAPT 2921/4885 |
| US-12281098-B2 | Five-membered-fused six-membered compound, preparation method, pharmaceutical composition and use | IRAK4, IRAK2, TRAF6 | POLB 3698/4885L3MBTL1 4347/4885MAPT 1557/4885 |
| US-12629367-B2 | Five-membered ring-fused six-membered ring compound, preparation method therefor, and pharmaceutical composition and use thereof | IRAK4, IRAK1, IRAK2 | POLB 4658/4885L3MBTL1 4422/4885MAPT 2954/4885 |
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | POLB 4774/4885L3MBTL1 3943/4885MAPT 1478/4885 |
| US-20250255863-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, IRAK1, IRAK2 | POLB 4214/4885L3MBTL1 3799/4885MAPT 2921/4885 |
| US-12343343-B2 | Five-membered ring-fused six-membered ring compound, preparation method therefor, and pharmaceutical composition and use thereof | IRAK4, IRAK1, IRAK2 | POLB 4214/4885L3MBTL1 3799/4885MAPT 2921/4885 |
| US-20250214972-A1 | FIVE-MEMBERED-FUSED SIX-MEMBERED COMPOUND, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE | IRAK4, IRAK2, TRAF6 | POLB 3698/4885L3MBTL1 4347/4885MAPT 1557/4885 |
| US-20130345240-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | POLB 4774/4885L3MBTL1 3943/4885MAPT 1478/4885 |
| US-20250255864-A1 | FIVE-MEMBERED RING-FUSED SIX-MEMBERED RING COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | IRAK4, IRAK1, IRAK2 | POLB 4214/4885L3MBTL1 3799/4885MAPT 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.